Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:37:52.362Z.
Calculation as of: 2026-10-06T15:37:52.362Z.
Quote observation: 2026-10-06T15:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$490.16M
Price/FCF Ratio
11.93
TTM Avg
8.08
3Y Avg
11.34
5Y Avg
14.47
Market Cap
$509.10M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$514.28M
Price/FCF Ratio
1066.98
TTM Avg
838.04
3Y Avg
838.04
5Y Avg
838.04
Market Cap
$479.89M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $500.37M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $491.69M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $490.16M | 11.93 | 8.08 | 11.34 | 14.47 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $514.28M | 1066.98 | 838.04 | 838.04 | 838.04 |
| Arvinas, Inc. (ARVN)vs › | $482.94M | N/A | 5.51 | 5.54 | 11.44 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $479.89M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $521.19M | N/A | 0.26 | 0.26 | 0.26 |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.20M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $522.43M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
